Articles by: Evan Dion

Amgen Reports Serious Adverse Events in Cancer Treatment Trial

Amgen (AMGN) said Wednesday that an early-stage study of an investigational myeloma treatment showed serious adverse events. The study of AMG 420 for relapsed and/or refractory multiple myeloma involved 42 patients who had experienced progression after at least two prior lines of treatment. They were given AMG 420 in varying doses up to 800 micrograms per day. The maximum tolerated […]

by × June 5, 2019 ×